These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2853721)
1. A prospective study of antibodies to Epstein-Barr virus DNase and viral capsid antigen for prognostication of patients with nasopharyngeal carcinoma. Hsu MM; Chen JY; Chen CJ Taiwan Yi Xue Hui Za Zhi; 1988 Oct; 87(10):984-8. PubMed ID: 2853721 [No Abstract] [Full Text] [Related]
2. Frequency and levels of antibodies to Epstein-Barr virus-specific DNase are elevated in patients with nasopharyngeal carcinoma. Cheng YC; Chen JY; Glaser R; Henle W Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6162-5. PubMed ID: 6255477 [TBL] [Abstract][Full Text] [Related]
3. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups. Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990 [TBL] [Abstract][Full Text] [Related]
4. Occurrence of Epstein-Barr virus deoxyribonuclease enzyme activity-neutralizing antibodies. An index of Epstein-Barr virus disease. Bardy B; Morinet F; Pérol Y Intervirology; 1989; 30(1):36-43. PubMed ID: 2542178 [TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls. Henle W; Henle G; Ho JH IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525 [No Abstract] [Full Text] [Related]
6. Epstein-Barr virus is not associated with head and neck neoplasms other than nasopharyngeal carcinoma. Kottaridis SD; Goula I; Kiparissiadis P Neoplasma; 1982; 29(3):327-31. PubMed ID: 6290911 [No Abstract] [Full Text] [Related]
7. Independent effect of EBV and cigarette smoking on nasopharyngeal carcinoma: a 20-year follow-up study on 9,622 males without family history in Taiwan. Hsu WL; Chen JY; Chien YC; Liu MY; You SL; Hsu MM; Yang CS; Chen CJ Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1218-26. PubMed ID: 19336547 [TBL] [Abstract][Full Text] [Related]
8. Serological and immunohistological assessment of Epstein-Barr virus infection in Sicilian patients with suspected nasopharyngeal carcinoma. Ammatuna P; de Thè G; Speciale R; Sammartano F; Arista S; Zerillo G Microbiologica; 1988 Apr; 11(2):89-94. PubMed ID: 2841559 [TBL] [Abstract][Full Text] [Related]
9. Antibody response to Epstein-Barr-virus-specific DNase in 13 patients with nasopharyngeal carcinoma in Taiwan: a retrospective study. Chen JY; Hwang LY; Beasley RP; Chien CS; Yang CS J Med Virol; 1985 Jun; 16(2):99-105. PubMed ID: 2989423 [TBL] [Abstract][Full Text] [Related]
10. The genetic and antigenic basis for the IgA antibody response to Epstein-Barr viral capsid antigen. Ng MH; Ho HC; Kwan HC IARC Sci Publ (1971); 1978; (20):449-58. PubMed ID: 215527 [No Abstract] [Full Text] [Related]
11. Antibody to Epstein-Barr virus-specific DNase in patients with nasopharyngeal carcinoma. Chen JY; Liu MY; Lynn TC; Yang CS Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1982 Nov; 15(4):255-61. PubMed ID: 6305599 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of IgG and IgA type antibodies to capsid and early antigens of the Epstein-Barr virus in the diagnosis of nasopharyngeal carcinoma]. Mendoza J; Rojas A; de la Rosa M; Amador JM; Expósito J; Esquivias J Med Clin (Barc); 1991 Nov; 97(16):609-11. PubMed ID: 1662737 [TBL] [Abstract][Full Text] [Related]
13. [The clinical usefulness of the serological study of IgG antibodies and IgA against the antigens associated with the Epstein-Barr virus in patients with nasopharyngeal carcinoma]. Amador García JM; Mendoza Montero J; Expósito Hernández J; Salinero Hernández J; Esquivias López-Cuerpo J; Ballesteros García P Acta Otorrinolaringol Esp; 1992; 43(1):31-6. PubMed ID: 1316136 [TBL] [Abstract][Full Text] [Related]
14. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC). Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561 [TBL] [Abstract][Full Text] [Related]
15. Malaria antibody levels in patients with nasopharyngeal carcinoma. Yadav M; Prasad U Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462 [TBL] [Abstract][Full Text] [Related]
16. Presence of Epstein-Barr virus specific IgA in saliva of nasopharyngeal carcinoma patients: their activity, origin and possible clinical value. Desgranges C; de-The G IARC Sci Publ (1971); 1978; (20):459-69. PubMed ID: 215528 [No Abstract] [Full Text] [Related]
17. [Relationship between natural cytotoxicity activity, Epstein-Barr virus (EBV) antibody titer and clinical status in nasopharyngeal carcinoma patients]. Mu M Zhonghua Er Bi Yan Hou Ke Za Zhi; 1988; 23(1):46-9. PubMed ID: 2856431 [No Abstract] [Full Text] [Related]
18. Nasopharyngeal mucosal changes in EB virus VCA-IgA antibody positive persons. Li EJ; Tan BF; Zeng Y; Wang PZ; Zhong JM; Deng H; Zhu CS; Wei JN; Pan WJ Chin Med J (Engl); 1985 Jan; 98(1):25-30. PubMed ID: 2988864 [No Abstract] [Full Text] [Related]
19. Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals. Zhu XX; Zeng Y; Wolf H Int J Cancer; 1986 May; 37(5):689-91. PubMed ID: 3009331 [TBL] [Abstract][Full Text] [Related]
20. The capsid antigen of Epstein-Barr virus in nasopharyngeal carcinomas: comparison of serum antibody titre, cellular antigen content and histopathology. Falser N Arch Otorhinolaryngol; 1984; 239(1):15-23. PubMed ID: 6318710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]